CLEVELAND, Aug. 5, 2020 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that Kaohsiung Medical
University Chung-Ho Memorial Hospital (KMUH) in Kaohsiung City,
Taiwan has begun patient
treatments with the MRIdian® MR-Guided Radiation Therapy
System, a cutting-edge device that delivers personalized cancer
care by combining the latest innovations in precision radiation
delivery with ground-breaking MR-guidance. The first two
patients treated at KMUH on MRIdian were provided care for prostate
cancer and tumor lesions in the left lung. Both treatments took
advantage of MRIdian's automated beam-gating technology, protecting
surrounding organs at risk.
The MRIdian system utilizes on-table soft-tissue imaging to
allow clinicians to visualize cancer tumors with diagnostic-quality
anatomical detail that is unavailable with conventional
image-guided radiation therapy (IGRT) technologies. The system
combines real-time imaging with the ability to adapt the treatment
as needed, based on daily changes in tumor shape, size or position,
for greater accuracy. The device also provides automated
beam-gating, which stops the delivery of radiation when the tumor
moves outside of the target area or when healthy tissue moves into
the target range. Together, these features help protect healthy
tissue and critical organs, while precisely targeting the tumor
with a high dose of radiation. MRIdian provides a compelling level
of personalization, precision and accuracy.
"I am moved by the professionals from all over the world who
gathered at KMUH to complete the installation of our MRIdian system
during the COVID-19 pandemic," said Dr. Chun-Ming Huang, who is a physician in the
radiation oncology department at the hospital. "How exciting it is
to finally see everything that could not be seen in the past and to
treat our patients with online, real-time adaptive
radiotherapy."
"We're pleased to have KUMH join the growing list of hospitals
to offer the benefits of MRIdian to their patients," said
Paul Ziegler, Senior Vice President
of Sales and Marketing at ViewRay. "As hospitals explore ways to
deliver effective cancer treatments while also minimizing patient
visits during these challenging times, MRIdian's ability to deliver
radiation therapy in fewer treatment sessions becomes even more
valuable."
The MRIdian at Chung-Ho Memorial Hospital is the first in
Taiwan and the fifth in
Asia. Currently, 38 MRIdian
systems are installed at hospitals around the world, where they are
used to treat a wide variety of solid tumors and are the focus of
numerous ongoing research efforts. MRIdian has been the subject of
hundreds of peer-reviewed publications, scientific meeting
abstracts, and presentations. The number of patients treated on
MRIdian is nearly 10,000. For a list of treatment centers, please
visit https://viewray.com/mridian-locator.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs,
manufactures, and markets the MRIdian® radiation therapy system.
MRIdian is built upon a proprietary high-definition MR imaging
system designed from the ground up to address the unique challenges
and clinical workflow for advanced radiation oncology. Unlike MR
systems used in diagnostic radiology, MRIdian's high-definition MR
was purpose-built to address specific challenges, including beam
distortion, skin toxicity, and other concerns that potentially may
arise when high magnetic fields interact with radiation beams.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Private Securities Litigation Reform Act. Statements in this press
release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other
things, the rate of new orders, upgrades, and installations,
ViewRay's anticipated future operating and financial performance,
and ViewRay's conference calls to discuss its quarterly results.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the ability to commercialize MRIdian Linac
System, demand for ViewRay's products, the ability to convert
backlog into revenue, the timing of delivery of ViewRay's products,
the timing, length, and severity of the recent COVID-19
(coronavirus) pandemic, including its impacts across our businesses
on demand, operations and our global supply chains, the results and
other uncertainties associated with clinical trials, the ability to
raise the additional funding needed to continue to pursue ViewRay's
business and product development plans, the inherent uncertainties
associated with developing new products or technologies,
competition in the industry in which ViewRay operates, and overall
market conditions. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to ViewRay's business in general, see ViewRay's current
and future reports filed with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal
year ended December 31, 2019 and its
Quarterly Reports on Form 10-Q, as updated periodically with the
company's other filings with the SEC. These forward-looking
statements are made as of the date of this press release, and
ViewRay assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements,
except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/kaohsiung-medical-university-chung-ho-memorial-hospital-begins-patient-treatments-with-viewrays-mridian-linac-301106295.html
SOURCE ViewRay, Inc.